SPOTLIGHT: Endo plans for the future

The Wall Street Journal examines the work of Endo Pharmaceuticals in building up an impressive pain management portfolio and the risks it faces from early generic competition. Report (WSJ sub. req.)

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.